“Latest Stem Cells News”

Hematologists are not typical “first responders,” and many feel ill-equipped to act in an emergency situation. Dr. Nelson Chao of Duke University hopes that those who attend the Emergency Preparedness Education Program Session this morning at 7:30 in La Nouvelle Ballroom C will feel more prepared to respond in times of crisis. Dr. Chao explains, “Preparation is an area that we don’t stress or think about enough, and we probably should. Our preparation would help both our patients and our staff in an emergency.” The session will include discussion of two recent crises and one hypothetical disaster that we will hopefully never face.

This year, the annual ASH meeting returns to New Orleans for the first time since Hurricane Katrina devastated the city. The effects of Hurricane Katrina were felt throughout the United States, but only those who lived through the natural disaster can truly understand its impact. Dr. Cindy Leissinger of Tulane University School of Medicine experienced the disaster first-hand and will share her unique perspective. She hopes that attendees will learn that the unimaginable can happen and that preparation can help in the recovery.

She will focus on the state of the medical community prior to Hurricane Katrina and what was learned from the disaster. One of her lessons involves the importance of communication. As she explains, “After Katrina, all of us were displaced — more than a million people were displaced — and that continued for many months for most of us. The most essential thing during that period for us as professionals and for our patients was the ability to communicate with each other. We had to scramble to put communication systems in place after Katrina — hopefully we learned some lessons that will help us to do a better job if another Katrina happens.” The lessons that Dr. Leissinger will present can be applied to other situations and are essential knowledge for all medical providers.

Questions about the H1N1 influenza outbreak from patients, families, and other providers are common for many hematologists this season. Some of these questions are relatively straightforward, including inquiries about the safety of vaccination and indications for prophylaxis. Other questions are more challenging, including how to vaccinate large patient populations efficiently, what to do when a staff member who has been at work becomes ill, and how to handle a worst-case scenario like an outbreak on a stem cell transplant unit. Dr. Richard Hatchett from the National Institute of Allergies and Infectious Disease will update the audience on the international H1N1 outbreak. He will address the current state of readiness and review public health measures. Dr. Hatchett’s expertise will be invaluable for hematologists and oncologists who care for populations vulnerable to influenza and other pathogens.

The session will conclude with Dr. Chao’s discussion of international preparedness for a potential radiological attack. Hematologists, oncologists, and experts in stem cell transplantation are uniquely qualified to care for survivors of a nuclear disaster and would be called on in such an emergency. International collaboration and preparation is necessary for the response to be effective. Dr. Chao will examine the nature of radiation injury and describe current international strategies for emergency response. In the event of a nuclear attack the response must be swift; preparation is essential. The unifying theme of preparedness promises to stimulate thought and discussion.

from http://www.hematology.org/Publications/ASH-News-Daily/2009/4627.aspx

Incoming search terms:

With veterinarians across the country training to use stem cells for tendon and ligament repair, a professor at the University of California, Davis (UC Davis) wants to take the technology a step further by applying them to chronic, cell-based diseases.

Richard Vulliet, DVM, is very early into the work. But he is optimistic about the evidence as it exists, of course, and he may have had a success.

Vulliet has treated four dogs with degenerative myelopathy with their own stem cells, which he prefers to call mesenchymal stem cells or pluripotent marrow stromal cells. The terminology has evolved and those names are more descriptive, he says (…)

Vulliet says he got interested in treating these conditions because he was working with mesenchymal stem cells and their interaction with connective tissue, and it was boring. Then he came across two papers.

In one of the papers, Japanese researchers described treating induced cardiomyopathy in experimental rats (Circulation 2005;112:1128-35). They reported that when the cells were injected into the myocardium, function improved, and there was evidence that the cells formed new vascular structures and produced collagen.

In the other paper, researchers at Tulane University in New Orleans induced spine injuries in experimental rats and treated them with mesenchymal stem cells. When they treated the animals immediately after the injury was induced, there was no apparent effect. However, when they waited one week before treating, they found that at five weeks, seven rats out of 12 could lift their trunks with their hind legs. By comparison, none of the 10 rats that were not treated showed similar signs of improvement.

Vulliet says notions of how mesenchymal stem cells might enhance the healing process have expanded beyond the idea that the cells migrate to a site of injury, differentiate into the proper type of cell and incorporate into the tissue. They might modulate immune response as well (…)

Stem cells are an ideal entrée into real-animal research, Vulliet explains. Experiments with human subjects and stem cells are not generally allowed, and federal regulators are unclear about whether they have the authority to regulate such research, since the cells are not drugs and usually are autologous tissue (…)

from http://news.vin.com/VINNews.aspx?articleId=14031

Incoming search terms: